subthread CNSI re posts 43, mainly 132,
and Scott's query in post 184
CNSI, Cambridge NeuroScience, my largest
position, trades right near book value.
The deal they did with Bayer means that
they are free not ever to worry about
finances for the entire development of
rhGGF2, their lead candidate for a number
of CNS diseases, but especially for MS for
remylenation. The Yahoo thread is very
good, and I would suggest read a dozen posts
starting with #1291...beware all, this is
an investment, not a trading opportunity and
I expect to hold most of my shares five years.
Of course, in this case, I have bought extra
shares at the current price, 3/4, so that if it
pops back up to around $1 1/2, I can take some
quick gains too...I like to trade part of my
investment, keeps me watching the thing and
my interest in the issue etc.
Most of the reason the stock is down right now
can probably be attributed to the price itself,
and the possibility of de-listing, but with
the Bayer deal, I hope that does not happen.
If it does...like I said, cnsi is an investment
and I wont get a pop any time soon--rhGGF2 is
not even in clinical trials yet as far as I
know...the query on recap.com just shows a
bunch of L's for lead, in like eight CNS
diseases.
Actually, if cnsi gets a new partner for something
else, say Cerestat again, then it will pop on
that, but who can say.
I see on the yahoo cnsi thread that the fellow
who has some sort of a friendly relationship with
the ceo is back...and he has a series of posts
there too now after phoning the company recently.
I never like to call...but I did email the company
and when I get a response I'll compare my notes
to his...I am astonished that a private investor
could have the sort of access that "YukonHusky"
seems to have...but I cant find any reason to
disbeleive the fellow either.
--MIke
|
